Navigation Links
RainDance Appoints Becker Chief Commercial Officer
Date:3/18/2008

GUILFORD, Conn., March 18 /PRNewswire/ -- RainDance Technologies, Inc., a developer of NanoReactor droplet-based microfluidic technology, today announced the appointment of Stephen E. Becker as Vice President, Commercial Officer, effective immediately.

"Mr. Becker will be responsible for continuing the growth of the company's commercial operations as it prepares for the launch of its first life science offering," said Chris McNary, President and Chief Executive Officer, RainDance Technologies. "These duties will include the continued development of the sales channels, leading customer service and support programs, and development of the strategic marketing plan."

The RainDance platform combines emulsion-based droplets and microfluidics to enable a host of existing applications in the company's nano-scale format, including genomic analysis, cell-based assays, and single molecule detection. Samples such as cells, nucleic acids, proteins, beads, and chemical compounds are encapsulated in individual micron-sized droplets on assay-specific microfludic chips. Since each droplet is the equivalent of a well in a microtiter plate, the RainDance platform can process and analyze up to 10,000 samples per second with unparalleled accuracy.

Becker joins RainDance from Agilent Technologies, where he served as Senior Sales Manager in the company's Americas Field Operations. There, he led the commercial introduction of novel genetic and epigenetic microarray assays that achieved over 20% growth rates in 2006 and 2007 in the research and molecular diagnostics markets. At GE Healthcare (formerly Amersham Pharmacia Biotech), Becker held several senior management assignments, including Director, Gene and Protein Discovery, and Director, Business Support. He also held sales management positions at Spectrum Chemical Manufacturing Corporation and Curtin Matheson Scientific, Inc. Becker received a bachelor's degree in biology from St. Mary's College of California.

"The RainDance droplet technology is a new tool that will allow scientists to accelerate their research through the advantages provided by nano-scale reactions at unparalleled assay speeds in the life science, diagnostic, and industrial markets," said McNary. "Mr. Becker's broad experiences will help us develop best-in-class commercial processes that support the introduction of our exciting technology."

About RainDance Technologies, Inc.

RainDance Technologies, Inc., is a biomedical technology company devoted to developing and commercializing a proprietary droplet-based microfluidics platform. The core of our technology is the generation of stable, nano-liter sized droplets that act as the functional equivalent of a test tube, or a well on a microtiter plate. Each droplet can encapsulate an individual sample of cells or reagents for both preparative and analytical life science and chemical analysis applications. RainDance recognizes that the rate and scale of research are accelerating dynamically, and for researchers to keep pace with these demands, they need the benefits of high-quality individualized reactions generated on a massive scale. Our vision is to be the worldwide leader in massively parallel sample processing and analytical solutions that provide a new standard of data quality.

RainDance has developed instrumentation and disposable microfluidic circuits that enable researchers to generate experimental results faster than existing methodologies, with increased throughput and decreased experimental variability. We will provide these tools to academic and commercial researchers working on a variety of basic and applied research applications. Our proprietary emulsion chemistries and microfluidic manufacturing process allow our platform to miniaturize many biological and chemical assays. These same core attributes will allow the RainDance platform to perform biological and chemical applications previously unimaginable or unaffordable using conventional laboratory or microfluidic techniques.

The company was founded in 2004 by scientists from Harvard University, the Medical Research Centre in Cambridge, and the ESPCI in Paris. The promise of this technology has attracted an outstanding Scientific Advisory Board, including three Nobel Prize winners (Jean-Marie Lehn, Sir Aaron Klug, and Dr. Richard Roberts) and Sir Gregory Winter.

The company's areas of focus include genomics, proteomics, cell biology, and molecular diagnostics. Importantly, we continue to expand our capabilities by partnering with the research community and commercial development partners to generate novel applications of the core RainDance technology.

For more information, please visit http://www.raindancetechnologies.com.


'/>"/>
SOURCE RainDance Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. RainDance Technologies Appoints McNary President and CEO
2. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
3. Codexis Appoints Singapore Laboratories Managing Director
4. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
5. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
6. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
7. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
8. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
9. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
10. NeurogesX Appoints New Director to the Board
11. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... BIRMINGHAM, AL (PRWEB) , ... June 28, 2017 ... ... of new spinal technologies, is pleased to announce the 500th case using the ... fusion system with uniquely designed titanium screws. SiCure can be implanted in ...
(Date:6/28/2017)... ... 2017 , ... Supplies of the critical medical isotope molybdenum-99 (Mo-99) are secure ... Nuclear Medicine and Molecular Imaging (SNMMI) 2017 annual meeting in Denver, Colorado in June. ... to 40 million nuclear medicine procedures worldwide every year. (1) , Sally Schwarz, ...
(Date:6/27/2017)... Shirley, NY (PRWEB) , ... June 27, 2017 , ... ... lift assist and ambulation aid in one device. This assistive aid lifts patients safely ... a safety harness and motorized lift mechanics. The Mobility Assist is the latest in ...
(Date:6/26/2017)... , ... June 26, 2017 , ... ... Melissa Kirkegaard, the former Associate Director of Product Development R&D at Allergan and ... pharmaceutical products at both start-up and established biopharma companies, has joined the firm ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
Breaking Biology News(10 mins):